Sara Nagy1,2, Sabine Schädelin3, Patricia Hafner1, Ulrike Bonati1,2, Delia Scherrer1, Selina Ebi1, Simone Schmidt1, Anna-Lena Orsini1,2, Oliver Bieri4, Dirk Fischer1. 1. Division of Neuropaediatrics, University of Basel Children's Hospital, University of Basel, Basel, Switzerland. 2. Department of Neurology, University Hospital Basel, University of Basel, Basel, Switzerland. 3. Clinical Trial Unit, University of Basel, Basel, Switzerland. 4. Department of Radiology, Division of Radiological Physics, University of Basel Hospital, University of Basel, Basel, Switzerland.
Abstract
INTRODUCTION: The definition of reliable outcome measures is of increasing interest in patients with Duchenne muscular dystrophy (DMD). METHODS: In this retrospective study, we analyzed the longitudinal reliability of clinical and radiological endpoints in 29 ambulant patients with DMD. Clinical outcome measures included motor function measure (MFM) and timed function tests, while quantitative MRI data were mean fat fraction (MFF) and T2 relaxation time of thigh muscles. Statistical analysis was based on 3-, 6-, and 12-month follow-up data. RESULTS: Quantitative MRI using the MFF was the most sensitive and powerful marker of disease progression with a sample size of four at 1-year follow-up, followed by the D1 domain of MFM (standing and transfer function) with a sample size of 12. DISCUSSION: Our data support the longitudinal design of clinical trials over at least 12 months and the combinational use of clinical and radiological surrogate outcome measures.
INTRODUCTION: The definition of reliable outcome measures is of increasing interest in patients with Duchenne muscular dystrophy (DMD). METHODS: In this retrospective study, we analyzed the longitudinal reliability of clinical and radiological endpoints in 29 ambulant patients with DMD. Clinical outcome measures included motor function measure (MFM) and timed function tests, while quantitative MRI data were mean fat fraction (MFF) and T2 relaxation time of thigh muscles. Statistical analysis was based on 3-, 6-, and 12-month follow-up data. RESULTS: Quantitative MRI using the MFF was the most sensitive and powerful marker of disease progression with a sample size of four at 1-year follow-up, followed by the D1 domain of MFM (standing and transfer function) with a sample size of 12. DISCUSSION: Our data support the longitudinal design of clinical trials over at least 12 months and the combinational use of clinical and radiological surrogate outcome measures.
Authors: Hala Abdulhady; Hossam M Sakr; Nermine S Elsayed; Tamer A El-Sobky; Nagia Fahmy; Amr M Saadawy; Heba Elsedfy Journal: Acta Myol Date: 2022-03-31
Authors: Sean C Forbes; Harneet Arora; Rebecca J Willcocks; William T Triplett; William D Rooney; Alison M Barnard; Umar Alabasi; Dah-Jyuu Wang; Donovan J Lott; Claudia R Senesac; Ann T Harrington; Erika L Finanger; Gihan I Tennekoon; John Brandsema; Michael J Daniels; H Lee Sweeney; Glenn A Walter; Krista Vandenborne Journal: Radiology Date: 2020-04-14 Impact factor: 11.105
Authors: Thom T J Veeger; Nienke M van de Velde; Kevin R Keene; Erik H Niks; Melissa T Hooijmans; Andrew G Webb; Jurriaan H de Groot; Hermien E Kan Journal: NMR Biomed Date: 2022-02-05 Impact factor: 4.478
Authors: Nienke M van de Velde; Melissa T Hooijmans; Aashley S D Sardjoe Mishre; Kevin R Keene; Zaïda Koeks; Thom T J Veeger; Iris Alleman; Erik W van Zwet; Jan-Willem M Beenakker; Jan J G M Verschuuren; Hermien E Kan; Erik H Niks Journal: Neurology Date: 2021-06-23 Impact factor: 9.910